Article
Gaboxadol Increases Resting Theta and Alpha Power without Affecting Evoked Responses in Fragile X Syndrome in a Home-based Setting
2025-10-24
Abstract excerpt
<title>Abstract</title> <p> <bold>Background:</bold> Fragile X syndrome (FXS) lacks FDA-approved treatments despite various small molecules contributing to phenotypic rescue in the <italic>FMR1</italic> knockout (KO) mouse model. Translation from the mouse model has been hampered by phenotypic heterogeneity that contributes to participation barriers among participants who are most affected and may be unable t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 42a49d13-6f45-58ec-8792-27b617370ca3
- DOI
- 10.21203/rs.3.rs-7871579/v1
